Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Jaguar Health Inc (JAGX)

Jaguar Health Inc (JAGX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 28,745
  • Shares Outstanding, K 46,363
  • Annual Sales, $ 4,420 K
  • Annual Income, $ -32,150 K
  • 60-Month Beta 0.71
  • Price/Sales 6.78
  • Price/Cash Flow N/A
  • Price/Book 2.73
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -21.68
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 11/18/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.23
  • Number of Estimates 2
  • High Estimate -0.19
  • Low Estimate -0.28
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.02%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.56 +5.50%
on 11/21/19
1.22 -51.25%
on 11/12/19
-0.13 (-17.96%)
since 10/21/19
3-Month
0.56 +5.50%
on 11/21/19
1.60 -62.83%
on 09/17/19
-0.69 (-53.53%)
since 08/21/19
52-Week
0.56 +5.50%
on 11/21/19
36.39 -98.37%
on 03/18/19
-30.91 (-98.11%)
since 11/21/18

Most Recent Stories

More News
Jaguar Health Subsidiary Napo Pharmaceuticals to Host Facebook Live "HIV Community Conversation" Event with Transgender Advocate Yonce Jones November 22, 2019 at 3 p.m. Eastern

SAN FRANCISCO, CA / ACCESSWIRE / November 21, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), today announced that the Company's wholly-owned subsidiary, Napo Pharmaceuticals, Inc....

JAGX : 0.59 (-4.84%)
Article About Jaguar Health Published in Fall 2019 Issue of MicroCap Review Magazine

SAN FRANCISCO, CA / ACCESSWIRE / November 20, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), today announced that an article about the Company appears in the Fall 2019 issue of MicroCap...

JAGX : 0.59 (-4.84%)
Jaguar Health, Inc. Reports 2019 Third Quarter Financial Results

JAGX : 0.59 (-4.84%)
Jaguar Health Announces that Interim Analysis Requirement Met in Phase 2 HALT-D Study Evaluating Mytesi (Crofelemer) for Prevention and Prophylaxis of Diarrhea in Breast Cancer Patients

SAN FRANCISCO, CA / ACCESSWIRE / November 14, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), today announced that Georgetown University's Data Safety Monitoring Committee ("DSMC")...

JAGX : 0.59 (-4.84%)
Jaguar Health Appoints Ian Wendt Vice President, Commercial Strategy

Reminder: Company to Host Investor Call Nov. 14th at 9 a.m. Eastern Regarding Interim Analysis of HALT-D Study of Mytesi (Crofelemer) for Prevention of Diarrhea in Breast Cancer Patients, Q3 Financials...

JAGX : 0.59 (-4.84%)
Jaguar Health to Host Investor Call Nov. 14th at 9 a.m. Eastern Regarding Interim Analysis of HALT-D Study of Mytesi (Crofelemer) for Prevention of Diarrhea in Breast Cancer Patients, Q3 Financials & Business Updates

Company Plans to File Q3 2019 10-Q on November 14, 2019

JAGX : 0.59 (-4.84%)
Jaguar Health Subsidiary Napo Pharmaceuticals Enters ex-U.S. Distribution Agreement for Mytesi (Crofelemer) with TannerGAP, Inc.

SAN FRANCISCO, CA / ACCESSWIRE / October 30, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), today announced that the Company's wholly-owned subsidiary, Napo Pharmaceuticals, Inc....

JAGX : 0.59 (-4.84%)
Jaguar Health Announces Completion of Preclinical Studies of Lechlemer, the Company's Human Drug Product Candidate for Cholera and Acute Infectious Diarrhea

Napo Pharmaceuticals, Jaguar's Subsidiary, Received Preclinical Services from the National Institute of Allergy and Infectious Diseases for the Studies

JAGX : 0.59 (-4.84%)
Jaguar Health's Study Shows Mytesi (Crofelemer) May Support Treatment of Diarrhea in Cancer Patients Receiving Targeted Therapy While Also Enabling Maintenance and Tolerability of a Higher Dose of the Selected TKI

SAN FRANCISCO, CA / ACCESSWIRE / October 22, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced additional findings today from the recently completed preclinical study evaluating...

JAGX : 0.59 (-4.84%)
MicroCap Rodeo Investor Conference - Lineup for October 15 and 16, 2019

The MicroCap Rodeo's inaugural event is set for October 15, and 16, 2019 in Austin Texas at the Hilton downtown Austin. Focused on the best ideas concept, the MicroCap Rodeo brings some of the best stories...

JAGX : 0.59 (-4.84%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Weakening short term outlook on maintaining the current direction.

The current trending strength of the market is Weak.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade JAGX with:

Business Summary

Jaguar Health, Inc. is a natural-products pharmaceuticals company. It focused on developing and commercializing novel, sustainably derived gastrointestinal products for both human prescription use and animals. The company through its subsidiary Napo Pharmaceuticals Inc., focuses on developing and commercializing...

See More

Key Turning Points

2nd Resistance Point 0.66
1st Resistance Point 0.64
Last Price 0.59
1st Support Level 0.60
2nd Support Level 0.58

See More

52-Week High 36.39
Fibonacci 61.8% 22.70
Fibonacci 50% 18.47
Fibonacci 38.2% 14.25
Last Price 0.59
52-Week Low 0.56

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar